FluoGuide is trading at SEK 30.00, down 5.7% today, with no clear catalyst identified to explain the move.

  • No fresh company announcements or earnings reports were released on August 5–6, 2026, to account for the drop from its recent stable range of SEK 31–32.
  • Recent news has been broadly positive, including strong Phase 2 data in oral head and neck cancer and a reiterated 2026 outlook.
  • The price action likely reflects standard volatility common in thinly covered small-cap biotech stocks rather than a fundamental shift.